// App-Quantinova.ai

P186 : Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis

Researchers

Presenter

  • Atul Deodhar

Principal Investigators

  • Andrew Blauvelt

  • Sergio Schwartzman

  • Carlo Salvarani

  • Meghan Feely

  • Andris Kronbergs

  • Nadia Eberhart

  • Danting Zhu

  • Elsa Mevel

  • Thorsten Holzkaemper

  • Eswar Krishnan

  • Mark Lebwohl

  • Proton Rahman

  • Helena Marzo-Ortega

  • Craig Bullock

Medical Centers

  • 72nd Street Medical Associates, Scarsdale, NY

  • Pathology, The Mount Sinai Hospital, New York, NY

  • Pediatrics, Oregon Health & Science University, Portland, OR

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Rheumatology, SOC Reumatologia, Azienda USL-IRCCS, Reggio Emilia, Italy

  • Rheumatology, Oregon Medical Research Center, Portland, OR

  • Epidemiology, Memorial University of Newfoundland, St.John's, Canada

Locations

  • United States

  • Italy

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Psoriatic arthritis

  • Spondyloarthritis

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved